<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04672525</url>
  </required_header>
  <id_info>
    <org_study_id>RIPH_2019_01</org_study_id>
    <nct_id>NCT04672525</nct_id>
  </id_info>
  <brief_title>Rifabutin Versus Rifampicin for Treatment of Staphylococcal PJI Treated With DAIR</brief_title>
  <acronym>RIFAMAB</acronym>
  <official_title>Rifabutin Versus Rifampicin for Treatment of Staphylococcal Prosthetic Joint Infection Treated With Debridement, Antibiotics and Implant Retention (DAIR Strategy): a Multicenter Randomized, Open-label, Non-inferiority Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tourcoing Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tourcoing Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rifampicin, is key in the treatment of staphylococcal PJIs. Rifabutin has a better profile of&#xD;
      tolerance than rifampicin regarding the risk of interaction with concomitant medications and&#xD;
      liver disorders. The hypothesis is that rifabutin may be an alternative antibiotic option as&#xD;
      efficient as rifampicin for the treatment of staphylococcal PJIs, with a better safety&#xD;
      profile. The investigator aim to demonstrate the non-inferiority of rifabutin as compared&#xD;
      with rifampicin prescribed in combination treatment for PJIs.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2021</start_date>
  <completion_date type="Anticipated">September 2026</completion_date>
  <primary_completion_date type="Anticipated">September 2025</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment failure</measure>
    <time_frame>At one year</time_frame>
    <description>Treatment failure defined as one of following events:&#xD;
The need for any further surgical procedure - i.e. implants removal, implants exchange or amputation;&#xD;
And/or PJI related death;&#xD;
And/or use of suppressive antibiotic therapy that was not planned before randomization</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Occurrence of serious adverse events (SAEs), including death (i.e. all cause)</measure>
    <time_frame>At the end of 12 weeks duration of antibiotic treatment planned</time_frame>
    <description>Proportion of patient which are free from SAEs occurrence, as defined by:&#xD;
-Patients who completed the entire 12 weeks duration of antibiotic treatment planned initially and; xWho did not experience grade 3-4 adverse events, including death, regardless of the link with antibiotic therapy; xWho did not experience adverse events which led to either to:&#xD;
Reduce the dosage or split the treatment to two take/day;&#xD;
Or stop any component of the antibiotic treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of any adverse event that could be related to rifampicin or rifabutin</measure>
    <time_frame>At the end of 12 weeks duration of antibiotic treatment planned</time_frame>
    <description>Number and rate of patients in each arm who experiences:&#xD;
Liver cytolysis (&gt;=2N for ALT AND/OR AST)&#xD;
Acute Kidney failure as defined by serum creatinine increase in KDIGO&#xD;
Digestive symptoms, including diarrhea&#xD;
Who required a modification of antibiotic dosage during the 12 weeks' period of antibiotic treatment&#xD;
Uveitis/ophthalmologic disorder&#xD;
Neurological disorder</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients from each arm who will complete the 12-week duration of rifampicin/rifabutin treatment, early termination of the planned 12 weeks' period of antibiotics</measure>
    <time_frame>At the end of 12 weeks duration of antibiotic treatment planned</time_frame>
    <description>Early termination rate will be measured in each arm, as the number of patients having stopped rifampicin or rifabutin before the planned 12 weeks period over the total number of patients enrolled in the studied arm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adherence to antibiotics regimen</measure>
    <time_frame>At the end of 12 weeks duration of antibiotic treatment planned</time_frame>
    <description>Adherence rate to medication will be measured as the number of days on which all doses were missed over the number of days of planned antibiotic therapy. Patients enrolled in the study will have to fill their pill count in a daily notebook.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life, as evaluated by EQ 5D 3L questionnaire</measure>
    <time_frame>At the end of the study follow up, an average of 24 months</time_frame>
    <description>Quality of life, as evaluated by the use EQ 5D 3L auto-questionnaire as used in previous randomized clinical trial on bone and joint infection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional prognosis using Oxford questionnaire evolution according to location of PJI</measure>
    <time_frame>At the end of the study follow up, an average of 24 months</time_frame>
    <description>Oxford Scores as used in previous randomized clinical trial on bone and joint infection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Long term efficacy of rifampicin and rifabutin treatment</measure>
    <time_frame>At the end of the study follow up, an average of 24 months</time_frame>
    <description>Long term efficacy: treatment failure, as defined for primary outcome, at 24 months</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">488</enrollment>
  <condition>Prosthetic Infection</condition>
  <arm_group>
    <arm_group_label>RIFAMPICIN</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patient with staphylococcal PJI, treated with DAIR strategy, and randomized in the control group will receive rifampicin in association with another antibiotic except rifabutin, as-per recommendations for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RIFABUTIN</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient with staphylococcal PJI treated with DAIR strategy, and randomized in the experimental group, will receive rifabutin in association with another antibiotic except rifampicin, as-per recommendations for 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rifabutin</intervention_name>
    <description>2 tablets of 150 mg per day rifabutin tablet daily for 12 weeks in 1 administration with a companion treatment</description>
    <arm_group_label>RIFABUTIN</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rifampicin</intervention_name>
    <description>10 mg/kg per day (range 600 mg to 1,200 mg) rifampicin tablet in 1 daily dose for 12 weeks with a companion treatment</description>
    <arm_group_label>RIFAMPICIN</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Hip or knee Prosthetic joint infection treated by debridement, antibiotic therapy&#xD;
             initiation and retention of prothesis (DAIR strategy)&#xD;
&#xD;
          2. Infected with at least one of the following microorganisms:&#xD;
&#xD;
               1. Staphylococcus aureus&#xD;
&#xD;
               2. Coagulase-negative staphylococci&#xD;
&#xD;
          3. Microorganisms susceptible to rifampicin and at least one other antibiotic suitable&#xD;
             for the treatment of PJI (e.g., penicillin, fluoroquinolone, (doxy/mino)cycline,&#xD;
             oxazolidinone, cotrimoxazole, daptomycin, glycopeptide, macrolide, fusidic acid),&#xD;
             regardless of sensitivity to methicillin.&#xD;
&#xD;
          4. Age ≥ 18 years&#xD;
&#xD;
          5. At least 2 days of appropriate (i.e., covering pathogen(s) identified in the&#xD;
             intraoperative samples) empirical agents are needed. Pre-randomization antimicrobial&#xD;
             therapy could be: flucloxacillin, oxacillin, vancomycin, daptomycin. β-lactam plus&#xD;
             β-lactamase-inhibitors (e.g. ampicillin+sulbactam, piperacillin+tazobactam),&#xD;
             cephalosporins (except ceftazidime), carbapenems, teicoplanin, ceftaroline,&#xD;
             ceftobiprole.&#xD;
&#xD;
          6. Signed Inform consent&#xD;
&#xD;
          7. Patient having the rights to French social insurance&#xD;
&#xD;
          8. For women of childbearing potential i.e. fertile, following menarche and until&#xD;
             becoming post-menopausal unless permanently sterile and excluding&#xD;
             oestroprogestative-based contraception, any effective contraceptive: vasectomy (for&#xD;
             men), intrauterine device copper, feminine sterilization, condom, sexual abstinence is&#xD;
             required. A postmenopausal state is defined as no menses for 12 months without an&#xD;
             alternative medical cause&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Suspicion of reduce absorption of oral treatment due to abdominal disorder Known or&#xD;
             suspected malabsorption (imperfect absorption of food material by the small intestine)&#xD;
&#xD;
          2. Polymicrobial infection due to other than staphylococcus species susceptible to&#xD;
             rifampicin&#xD;
&#xD;
          3. Known or suspected allergy to rifabutin and/or rifampicin&#xD;
&#xD;
          4. Diagnosis of endocarditis associated to PJI&#xD;
&#xD;
          5. Renal transplant or Chronic kidney disease with an eGFR of less than 30ml/min/1.73m²&#xD;
&#xD;
          6. Other Solid Organ Transplant&#xD;
&#xD;
          7. Liver cirrhosis, Child-Pugh score C&#xD;
&#xD;
          8. Any other concomitant infection which required a prolonged course of intravenous&#xD;
             antibiotic therapy&#xD;
&#xD;
          9. Oestroprogestative-based contraception&#xD;
&#xD;
         10. Oral anticoagulant drugs&#xD;
&#xD;
         11. Other drug-drug interaction that contraindicated rifampicin or rifabutin&#xD;
&#xD;
         12. Porphyria&#xD;
&#xD;
         13. Unable to take oral treatment&#xD;
&#xD;
         14. Receive empirical postoperative antibiotic treatment by rifampicin or rifabutin prior&#xD;
             to randomization&#xD;
&#xD;
         15. Pregnancy or lactating women&#xD;
&#xD;
         16. Curator or guardianship or patient placed under judicial protection&#xD;
&#xD;
         17. Participation in other interventional research during the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric SENNEVILLE, Md PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CH Tourcoing</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eric SENNEVILLE, MD PhD</last_name>
    <phone>0320694949</phone>
    <email>esenneville@ch-tourcoing.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Solange TREHOUX</last_name>
    <phone>0320694280</phone>
    <email>strehoux@ch-tourcoing.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU Amiens Picardie</name>
      <address>
        <city>Amiens</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Benoit BRUNSCHWEILER</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Besançon</name>
      <address>
        <city>Besançon</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Kévin BOUILLER</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Fréderic-Antoine DAUCHY</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>APHP Hôpital Ambroise Paré</name>
      <address>
        <city>Boulogne-Billancourt</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Aurélien DINH</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHRU Brest</name>
      <address>
        <city>Brest</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Severine ANSART</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Dijon Bourgogne</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Lionel PIROTH</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHRU Lille</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique de la Sauvegarde</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Anne-Laure BLANC</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospices Civils de Lyon</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Tristan FERRY</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Nice</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Johan COURJON</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH Annecy Genevois</name>
      <address>
        <city>Pringy</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Violaine TOLSMA</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH Cornouaille</name>
      <address>
        <city>Quimper</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Lydie KHATCHATOURIAN</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Rennes</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Cédric ARVIEUX</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHRU Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Cécile RONDE-OUSTAU</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH Tourcoing</name>
      <address>
        <city>Tourcoing</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Eric SENNEVILLE</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHRU Tours</name>
      <address>
        <city>Tours</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Louis BERNARD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 11, 2020</study_first_submitted>
  <study_first_submitted_qc>December 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 17, 2020</study_first_posted>
  <last_update_submitted>March 29, 2021</last_update_submitted>
  <last_update_submitted_qc>March 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rifampin</mesh_term>
    <mesh_term>Rifabutin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

